Literature DB >> 22033405

Ganodermanontriol (GDNT) exerts its effect on growth and invasiveness of breast cancer cells through the down-regulation of CDC20 and uPA.

Jiahua Jiang1, Andrej Jedinak, Daniel Sliva.   

Abstract

Ganoderma lucidum is a medicinal mushroom that has been recognized by Traditional Chinese Medicine (TCM). Although some of the direct anticancer activities are attributed to the presence of triterpenes-ganoderic and lucidenic acids-the activity of other compounds remains elusive. Here we show that ganodermanontriol (GDNT), a Ganoderma alcohol, specifically suppressed proliferation (anchorage-dependent growth) and colony formation (anchorage-independent growth) of highly invasive human breast cancer cells MDA-MB-231. GDNT suppressed expression of the cell cycle regulatory protein CDC20, which is over-expressed in precancerous and breast cancer cells compared to normal mammary epithelial cells. Moreover, we found that CDC20 is over-expressed in tumors when compared to the tissue surrounding the tumor in specimens from breast cancer patients. GDNT also inhibited invasive behavior (cell adhesion, cell migration, and cell invasion) through the suppression of secretion of urokinase-plasminogen activator (uPA) and inhibited expression of uPA receptor. In conclusion, mushroom GDNT is a natural agent that has potential as a therapy for invasive breast cancers.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22033405     DOI: 10.1016/j.bbrc.2011.10.055

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

Review 1.  Functional characterization of Anaphase Promoting Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis.

Authors:  Jinfang Zhang; Lixin Wan; Xiangpeng Dai; Yi Sun; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-02-22

2.  Identification of differentially expressed protein-coding genes in lung adenocarcinomas.

Authors:  Luyao Wang; Shicheng Li; Yuanyong Wang; Zhenxue Tang; Chaolong Liu; Wenjie Jiao; Jia Liu
Journal:  Exp Ther Med       Date:  2019-12-06       Impact factor: 2.447

Review 3.  Targeting Cdc20 as a novel cancer therapeutic strategy.

Authors:  Lixia Wang; Jinfang Zhang; Lixin Wan; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Pharmacol Ther       Date:  2015-04-04       Impact factor: 12.310

4.  Cell division cycle 20 promotes cell proliferation and invasion and inhibits apoptosis in osteosarcoma cells.

Authors:  Guanning Shang; Xu Ma; Gang Lv
Journal:  Cell Cycle       Date:  2017-12-22       Impact factor: 4.534

5.  Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.

Authors:  Fei Wu; Xiangpeng Dai; Wenjian Gan; Lixin Wan; Min Li; Nicholas Mitsiades; Wenyi Wei; Qiang Ding; Jinfang Zhang
Journal:  Cancer Lett       Date:  2016-10-22       Impact factor: 8.679

6.  Diosgenin exerts its tumor suppressive function via inhibition of Cdc20 in osteosarcoma cells.

Authors:  Cheng Long; Juan Chen; Hua Zhou; Tao Jiang; Xiang Fang; Dong Hou; Ping Liu; Hong Duan
Journal:  Cell Cycle       Date:  2019-01-22       Impact factor: 4.534

Review 7.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04

Review 8.  Cdc20: a potential novel therapeutic target for cancer treatment.

Authors:  Zhiwei Wang; Lixin Wan; Jiateng Zhong; Hiroyuki Inuzuka; Pengda Liu; Fazlul H Sarkar; Wenyi Wei
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction.

Authors:  Lixin Wan; Mingjia Tan; Jie Yang; Hiroyuki Inuzuka; Xiangpeng Dai; Tao Wu; Jia Liu; Shavali Shaik; Guoan Chen; Jing Deng; Marcos Malumbres; Anthony Letai; Marc W Kirschner; Yi Sun; Wenyi Wei
Journal:  Dev Cell       Date:  2014-05-27       Impact factor: 12.270

10.  NAHA, a novel hydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo.

Authors:  Jiahua Jiang; Anita Thyagarajan-Sahu; Viktor Krchňák; Andrej Jedinak; George E Sandusky; Daniel Sliva
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.